Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
Subbiah
Vivek
V
Trent
Jonathan C
JC
Kurzrock
Razelle
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D017024:Chemotherapy, Adjuvant; D017321:Clinical Trials, Phase I as Topic; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000187:drug effects* / Q000378:metabolism; D008875:Middle Aged; D054973:Perivascular Epithelioid Cell Neoplasms / Q000188:drug therapy* / Q000556:secondary; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D017346:Protein Serine-Threonine Kinases / Q000187:drug effects* / Q000378:metabolism; D011719:Pyrazines / Q000008:administration & dosage; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D058570:TOR Serine-Threonine Kinases; D019772:Topotecan / Q000008:administration & dosage; D017211:Treatment Failure
D001897:Boronic Acids; D047908:Intracellular Signaling Peptides and Proteins; D047428:Protein Kinase Inhibitors; D011719:Pyrazines; C401859:temsirolimus; D000069286:Bortezomib; D019772:Topotecan; D004317:Doxorubicin; C546842:MTOR protein, human; D017346:Protein Serine-Threonine Kinases; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus